Ultragenyx Pharmaceutical Inc. (FRA:UP0)

Ultragenyx Pharmaceutical Statistics

Total Valuation

FRA:UP0 has a market cap or net worth of EUR 1.86 billion. The enterprise value is 2.30 billion.

Market Cap	1.86B
Enterprise Value	2.30B

Important Dates

The last earnings date was Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	96.43M
Shares Outstanding	n/a
Shares Change (YoY)	+8.90%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.24
PB Ratio	-29.91
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.70
EV / Sales	4.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.73

Financial Position

The company has a current ratio of 2.48

Current Ratio	2.48
Quick Ratio	2.19
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.65
Interest Coverage	-8.63

Financial Efficiency

Return on equity (ROE) is -608.47% and return on invested capital (ROIC) is -28.45%.

Return on Equity (ROE)	-608.47%
Return on Assets (ROA)	-22.03%
Return on Invested Capital (ROIC)	-28.45%
Return on Capital Employed (ROCE)	-46.60%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	418,085
Profits Per Employee	-357,205
Employee Count	1,294
Asset Turnover	0.44
Inventory Turnover	17.71

Taxes

In the past 12 months, FRA:UP0 has paid 3.41 million in taxes.

Income Tax	3.41M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.31% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-55.31%
50-Day Moving Average	22.26
200-Day Moving Average	26.45
Relative Strength Index (RSI)	42.27
Average Volume (20 Days)	6

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.34

Income Statement

In the last 12 months, FRA:UP0 had revenue of EUR 573.19 million and -489.73 million in losses. Loss per share was -4.97.

Revenue	573.19M
Gross Profit	-158.42M
Operating Income	-455.66M
Pretax Income	-486.32M
Net Income	-489.73M
EBITDA	-425.85M
EBIT	-455.66M
Loss Per Share	-4.97

Balance Sheet

The company has 579.16 million in cash and 1.07 billion in debt, with a net cash position of -438.63 million.

Cash & Cash Equivalents	579.16M
Total Debt	1.07B
Net Cash	-438.63M
Net Cash Per Share	n/a
Equity (Book Value)	-62.17M
Book Value Per Share	-0.71
Working Capital	482.91M

Cash Flow

In the last 12 months, operating cash flow was -396.89 million and capital expenditures -5.11 million, giving a free cash flow of -402.00 million.

Operating Cash Flow	-396.89M
Capital Expenditures	-5.11M
Free Cash Flow	-402.00M
FCF Per Share	n/a

Margins

Gross margin is -27.64%, with operating and profit margins of -79.49% and -85.44%.

Gross Margin	-27.64%
Operating Margin	-79.49%
Pretax Margin	-84.84%
Profit Margin	-85.44%
EBITDA Margin	-74.29%
EBIT Margin	-79.49%
FCF Margin	n/a

Dividends & Yields

FRA:UP0 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.90%
Shareholder Yield	-8.90%
Earnings Yield	-26.33%
FCF Yield	-21.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:UP0 has an Altman Z-Score of -3.17 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.17
Piotroski F-Score	4